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Depolarizing GABA contributes to glutamatergic network rewiring in epilepsy 
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Abstract 
Objective: Rewiring of excitatory glutamatergic neuronal circuits is a major abnormality in epilepsy. 
Besides the rewiring of excitatory circuit, an abnormal depolarizing GABAergic drive has been 
hypothesized to participate in the epileptogenic processes. However, a remaining clinically relevant 
question is whether early post Status Epilepticus (SE) evoked chloride dysregulation is important for 
the remodeling of aberrant glutamatergic neuronal circuit.  
Methods: Osmotic mini-pumps were used to infuse intracerebrally a specific inhibitor of depolarizing 
GABAergic transmission as well as a functionally blocking antibody towards the pan-neurotrophin 
receptor p75 (p75
NTR
). The compounds were infused between 2 and 5 days after pilocarpine-induced 
SE. Immunohistochemistry for NKCC1, KCC2 and ectopic recurrent mossy fiber (rMF) sprouting as 
well as telemetric EEG and electrophysiological recordings were performed at day 5 and 2 months 
post-SE. 
Results: Blockade of NKCC1 after SE with the specific inhibitor bumetanide restored NKCC1 and KCC2 
expression, normalized chloride homeostasis and significantly reduced the glutamatergic recurrent 
mossy fiber sprouting (rMF) within the dentate gyrus. This mechanism partially involves p75
NTR
 
signaling as bumetanide application reduced SE-induced p75
NTR
 expression and functional blockade 
of p75
NTR
 decreased rMF sprouting. The early transient (3days) post-SE infusion of bumetanide 
reduced rMF sprouting and recurrent seizures in the chronic epileptic phase.  
Interpretation: Our findings show that early post-SE abnormal depolarizing GABA and p75
NTR
 
signalings foster a long lasting rearrangement of glutamatergic network that contributes to the 
epileptogenic process. This finding defines promising and novel targets to constrain reactive 
glutamatergic network rewiring in adult epilepsy. 
Keywords: mossy fiber sprouting, epilepsy, pan-neurotrophin receptor p75
NTR
, GABAergic signaling, 
NKCC1, KCC2, bumetanide. 
Abbreviations: TLE: temporal lobe epilepsy; SE: status epilepticus; DG: dentate gyrus; DGC: dentate 
gyrus granule cell; rMF: recurrent mossy fiber; p75
NTR
: pan neurotrophin receptor p75; KCC2: K
+
-Cl
-
 
co-transporter; NKCC1: Na
+
-K
+
-2Cl
-
 co-transporter. 
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Introduction 
Plastic remodeling of glutamatergic neuronal networks is one of the major pathophysiological 
processes observed in epileptic tissue and post-traumatic brain injuries (TBI) both in humans and 
animal models
1,2
. The understanding of the molecular mechanisms involved in this plastic remodeling 
is of particular importance since it creates a powerful hyperexcitable cerebral focus that drives 
recurrent disabling seizures
3-5
. This phenomenon, called reactive plasticity, is well documented in the 
dentate gyrus (DG), where ectopic dentate granule cell (DGC) axons (the recurrent mossy fibers 
[rMFs]) sprout and create a reverberant excitatory circuit between DGCs. This is involved in the 
formation of epileptiform bursts in patients with temporal lobe epilepsy (TLE) and TBI, as well as in 
animal models
6-13
. Although the molecular mechanisms are unclear, there is evidence supporting an 
active role of neurotrophin signaling
15-18
. However, the early post-SE molecular events that activate 
neurotrophin pathways and trigger the ectopic rMF growth remain elusive. Besides the rewiring of 
excitatory circuits, an abnormal depolarizing GABAergic drive has been hypothesized to participate in 
epileptogenic processes in adult brain. This includes the dysregulation of the neuronal specific K
+
-Cl
-
 
co-transporter KCC2 and the Na
+
-K
+
-2Cl
-
 co-transporter NKCC1 as reported in resected tissues from 
human TLE patients
19,20
 and animal models
21-23
. Indeed, bumetanide, a specific blocker of NKCC1, has 
been shown to have acute anticonvulsant action on chronic epileptic activity
25
. We have also 
previously shown that depolarizing GABAergic transmission triggers the upregulation of the pan-
neurotrophin receptor, p75
NTR
, in an acute injury model
24
.  
Here we have tested the hypothesis whereby the early alteration of chloride homeostasis following 
SE is a precipitating event involved in rMF sprouting establishment via the activation of p75
NTR
. We 
examined a novel therapeutic strategy based on the transitory blockade of NKCC1, early after SE (i.e. 
before the appearance of ictal activities), to reduce the ectopic sprouting and recurrent seizures in 
the chronic epileptic phase (i.e. several months after SE).  
We found that a functional establishment of ectopic rMF sprouting takes place concomitantly with 
altered expression of NKCC1 and KCC2 as early as day 5 post-SE in the rat pilocarpine model of TLE. 
Moreover, we were able to demonstrate that p75
NTR
 is upregulated and is involved in the formation 
of ectopic rMF sprouting. In turn, NKCC1 inhibition resulted in the decrease of post-SE p75
NTR
 
upregulation and the reduction of rMF sprouting. Finally, transitory blockade of NKCC1 few days 
after SE resulted in a significant reduction of rMF growth and recurrent seizures at the chronic stage. 
In conclusion, our findings pave a way to identify novel therapeutic strategies targeting cation-
chloride
 
co-transporters and p75
NTR
 signaling pathways to constrain abnormal glutamatergic network 
rewiring and chronic adult epilepsy. 
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Experimental procedures 
Animals. All experiments were approved by the Institute National de la Santé et de la Recherche 
Médicale (INSERM) through the local ethic committee (project number 66-15112012) and the 
European community council directive (2010/63/UE). Adult male Wistar rats had access to food and 
water ad libitum and were housed under a 12 h light/dark cycle at 22–24°C.  
Rat model of temporal lobe epilepsy. An animal model of temporal lobe epilepsy was obtained using 
adult male Wistar, as previously described
26
. Briefly, six weeks old male rats (Charles River and 
Janvier Laboratories) were treated with pilocarpine hydrochloride (360 mg/kg, i.p.; Sigma-Aldrich) 30 
minutes after scopolamine methyl nitrate (0,5 mg/kg, i.p.; Sigma-Aldrich). After 3h of Status 
Epilepticus (Stage V on Racine’s scale), convulsions were suppressed with diazepam (8 mg/kg, i.p.; 
Roche) and saline solution (0,9% NaCl; Sigma-Aldrich) was administrated subcutaneously. The 
success rate of the pilocarpine sessions was 67%, which is in accordance with other studies using 
adult rats, similar dose, and SE duration
27-28
. 
Bumetanide and p75
NTR
 antibody infusion. Osmotic minipumps and cannulae were implanted to 
continuously deliver bumetanide (B3023, Sigma-Aldrich). Rats were anaesthetized with 4.5% 
isoflurane and maintained with 2.5% isoflurane for surgery and placed on a heating pad to control 
body temperature. Rats were placed in a stereotaxic apparatus, a scalp incision was made, and a 0,8 
mm diameter hole was drilled through the skull (A/P -3.8; L/M +2.5; D/V 3.0) and a 3.0 mm long 28 
gauge cannula (Alzet brain infusion kit, Charles River) was inserted and secured to the skull with 
dental cement (Paladur, Hereaus). An osmotic mini-pump (Alzet mini-pumps 2002, Charles River) and 
tubing connected to the cannula were implanted subcutaneously over the back. Mini-pumps were 
filled with vehicle solution containing 0.3% of ethanol in 1M PBS with or without bumetanide 
(20μM). After surgery, rats were kept warm, received saline (0.9% NaCl, s.c.), and analgesic 
buprenorphine (0.03 mg/kg, s.c.) was administrated to minimize animal pain after surgery. In all 
experiments, infusions began at two days post-status Epilepticus and last for 3 days with a delivery 
rate of 0.5μl/hour ± 0.05 μl at body temperature, resulting into a quantity of bumetanide injected of 
86ng/24h during 3 days. For p75
NTR
 antibody infusion, mini-pumps contained vehicle solution (1M 
PBS), control rabbit IgG (dilution 1:300 in 1M PBS; sc-2027, Santa Cruz Biotechnology), or p75
NTR
 
antibody (dilution 1:300 in 1M PBS of 2mg/ml; final concentration of 6.67µg/ml; AB1554; Millipore). 
The mortality rate was 5-8% at 24h post-surgery. 
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qRT-PCR. Expressions of NKCC1 and KCC2 mRNA were detected by real-time quantitative PCR. Total 
RNAs were isolated from in toto hippocampi using Mini RNeasy kit (Qiagen). First strand cDNA was 
synthetized from 1mg of total cellular RNA Reverse Transcription QuantiTect kit (Qiagen) at 42°C for 
15min then 95°C for 3min in solution containing RNAases inhibitors, oligo-DTs, primers and dNTPs. 
Real-time PCR cycles were carried out for amplification of NKCC1, KCC2, and GAPDH using termal 
cycles (Eppendorf). Primers were designed and synthetized by Qiagen. RT-PCR was then carried out 
using 5mL of cDNA in a final reaction volume of 30mL using SYBER Green Real-time PCR Master Mix. 
Primers sequences are listed in Table 1. The relative copies are expressed in arbitrary unit.  
Western Blots. Animals were killed by decapitation after isoflurane anaesthesia and the hippocampi 
were quickly dissected out and flash-frozen in liquid nitrogen and stored at -80°C until processed. 
Brain tissue was homogenized in RIPA buffer (50mM Tris-HCl pH: 8; 150mM NaCl; SDS 0,1%; 
Deoxycholic Acid 0,5%; 1% triton X-100), containing 1 Complete Protease/Phosphatase Inhibitor 
Tablet (Thermofisher) and loaded with Laemmli 3X loading buffer. The samples were separated in 
7,5-20% SDS–PAGE gel (Criterion gel, Bio-Rad) and transferred to nitrocellulose membrane 
(Whatman). After blockade in Tris-buffered saline plus 5% BSA, we exposed membranes overnight at 
4°C to polyclonal rabbit KCC2-specific antibody diluted 1:2000 in blocking solution. 
Chemiluminescent detection was performed using horseradish peroxidase-conjugated rabbit-specific 
antibody diluted 1:3000 in blocking solution for 2h at room temperature and revealed using ECL-plus 
western blotting reagents (ECL-plus kit, Pierce Biotech). We measured signal intensities with the 
image analysis software G box (Syngene). Then, membranes were stripped using DTT/SDS in Tris-HCl, 
pH 7.0, and probed with rabbit anti-β3-tubulin or α-tubulin (Sigma, 1:20000) for normalization and 
signal detection and revelation following the same procedure. Quantification is performed using Get 
Plot Analyser plugin (Fiji). The antibodies are listed in Table 1. The relative expression levels are 
expressed in arbitrary unit.  
Immunohistochemstry. Rats were anaesthetized with isoflurane followed by pentobarbital 
(65mg/kg) and transcardiacally perfused with cold PBS (1M) prior to cold 4% paraformaldehyde in 
phosphate buffer saline (PBS). Brains were post-fixed overnight in 4% paraformaldehyde in PBS at 
4°C and then coronaly cut with a Leica VT1200S vibratome (60μm thick-sections). Sections (6 slices 
per condition) were then permeabilized and blocked in PBS with 0.3% Triton X-100 and 5% normal 
goat serum (NGS) for 1h at room temperature. Incubation with primary antibodies diluted in PBS 
with 5% NGS and 0.1% Triton X-100 was carried out at 4°C overnight (SPO was incubated additional 
24h at 4°C) using different primary antibodies (Table 1). After rinsing 3 times in PBS, slices were 
incubated with the corresponding Alexa Fluor-conjugated secondary antibodies diluted in PBS 
This article is protected by copyright. All rights reserved.
6 
(1:1000, Invitrogen) for 1h (SPO was incubated additional 2h) at room temperature and finally 
counterstained for 5 min with Hoechst 33258 (10μg/ml in PBS, Sigma-Aldrich).  
Quantification of KCC2 analysis was performed in blind. For plot analysis of KCC2 the intensity and 
distribution associated with the membrane or cytosolic regions in control, pilocarpine rats, 
pilocarpine vehicle-treated rats and pilocarpine bumetanide-treated rats were performed using 20X 
objective and Plot analysis using Fiji software. The same straight-line length (10µm) was applied from 
the nucleus to the external cell compartment of 50 cells from each condition. The plot profile values 
were analyzed and calculated the S.E.M. (error bars). The total fluorescence intensity analysis of 
KCC2 has been normalized to the number of NeuN-positive cells contained in the ROIs. The 3D object 
counter pluggin from Fiji software was used to count the number of cells.  
Acute slices preparation. Animals were deeply anaesthetized with chloral hyadrate (350 mg/kg, i.p.) 
and decapitated. The brain was removed rapidly, the hippocampi were dissected, and transverse 
400μm slices were cut in oxygenated (95% O2 and 5% CO2) modified artificial cerebrospinal fluid 
(mACSF) containing the following (in mM): 132 choline, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 7 MgCl2, 
0.5 CaCl2, and 8 D-glucose; using a Leica VT1000S tissue slicer (Leica VTS1200S, Germany). Slices 
were then transferred for rest at room temperature (1-3h) or 34°C (1h) for electrophysiological 
recordings in oxygenated (95% O2 and 5% CO2) normal artificial CSF (ACSF) containing the following 
(in mM): 126 NaCl, 3.5 KCl, 1.2 NaH2PO4, 26 NaHCO3, 1.3 MgCl2, 2.0 CaCl2, and 10 D-glucose, pH 7.4.  
In vitro electrophysiological recordings. Hippocampal slices were individually transferred to a 
recording chamber maintained at 30–32°C and continuously perfused (2 ml/min) with oxygenated 
normal or adapted ACSF containing 5 μM gabazine. Synchronized burst discharges were evoked by 
antidromic stimulation of the mossy fiber pathway in the CA3b area while recording local field 
potentials in the dentate granular layer using a DAM-80 amplifier (lowfilter, 0.1 Hz; highpass filter, 3 
KHz; World Precision Instruments, Sarasota, FL). Signals were analyzed off-line usingClampfit 9.2 
(PClamp) and MiniAnalysis 6.0.1 (Synaptosoft, Decatur, GA). Whole-cell patch-clamp recordings were 
done using a MultiClamp 700B amplifier (Molecular Devices, USA). The patch pipette solution 
contained the following (in mM): 18 KCl
-
, 111 K-gluconate, 0.5 CaCl2, 2NaOH, 10 glucose, 10 HEPES, 2
Mg-ATP, and 5 BAPTA, (pH adjusted to 7.3 with KOH). Patch pipettes were fabricated from 
borosilicate glass (Harvard Apparatus, Edenbridge, UK), and their resistance ranged from 6.5 to 7.5 
MΩ. Only cells with access resistances between 10 and 20 MΩ were accepted for analysis. 
Membrane potential was clamped at 60 mV. All membrane potential values were corrected for a 
liquid-junction potential of 10 mV. The reversal potential of GABAergic currents (EGABA) was 
determined from the current–voltage (I–V) relation obtained by sequentially clamping the 
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membrane at different voltage levels. GABA was photolyzed from the α-carboxy-2-nitrobenzyl 
(DPNI)-caged GABA compound (Tocris) using local uncaging as described previously
29
. Briefly, caged 
GABA (2.5 mM) was dissolved in the physiological solution and delivered at a flow rate of 1-3 μl/min 
to the vicinity of the patch-clamped cell using an Aladdin Programmable syringe pump (WPI, 
Sarasota, FL) and a syringe with an inner tip diameter of 100 μm. For local photolysis of caged GABA, 
the 405 nm output of a IQ Series laser diode module (Power Technology Inc.) was delivered to the 
slice via a multimode optical fiber through an Leica LUMPlanFl 40X water-immersion objective. The 
UV beam yielded an uncaging spot of 10 μm in diameter that was focused either at the soma or at 
dendrite at a distance of 100 μm from the soma
28
. At each location, current–voltage relationship was 
determined by varying the holding potential from −90 to −40 mV (10 mV steps). Duration of UV light 
stimuli was 50 ms. 
In vivo electrophysiological recordings. Scalp electroencephalographic (EEG) recordings were 
performed in freely-moving rats. To implant recording electrodes, rats were anaesthetized with 4.5% 
isoflurane and maintained at 2.5%, placed in stereotaxic frame, placed on a heating pad to control 
body temperature and prepared for aseptic surgery. A hole was drilled 2 mm posterior and 1.5 mm 
right to bregma. A screw connected to EEG transmitter was placed in the skull, and reference 
electrode was placed rostrally in the cerebellum. The screws were attached to the skull with dental 
cement and scalp closed. After surgery, rats were kept warm and received saline (0.9% NaCl, s.c.), 
and analgesic buprenorphine (0.03 mg/kg, s.c.) was administrated to minimize animal pain after 
surgery. After a 24h recovery, EEG (amplified (1000X), filtered at 0.16–97 Hz pass, acquired at 500 
Hz) was monitored using a telemetric system (Data Sciences International, St. Paul, MN) for 5 days, 
24 h per day; food and water were given ad libitum. 
Recordings were analyzed offline using Spike2 8.0. Tonic seizures were defined on the EEG as single 
or multiple 5-30Hz poly-spike of 5 fold SD amplitude and 10-30 s duration
13
.  
Statistical analysis. Data were expressed as means +/- S.E.M. Statistical analyses were performed 
using GraphpadPrism (GraphPad software 6.01). For comparison between groups with normal 
distribution, the two-sample unpaired or paired Student’s t test was used for two groups. When data 
were not normally distributed, the Mann–Whitney rank-sum test (for unpaired data) or the two 
sample Kolmogorov–Smirnov rank-sum test (for paired data) was used. The one-way ANOVA all-
Tukey test was used to compare multiples groups. 
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Results 
NKCC1 and KCC2 expression is altered at day 5 post-SE 
The expression of NKCC1 and KCC2 is known to be altered in TLE
19-23
. However, the temporal changes 
of these chloride transporters at early stages after SE remain elusive. We found that mRNA 
transcripts extracted from in toto hippocampi display an initial upregulation of NKCC1 and 
downregulation of KCC2 at day 1 post-SE (d1pSE) that returns to control levels 14 days post-SE 
(d14pSE) (Figure 1A; NKCC1; ctrl: 1 ± 0.11; d1: 2.10± 0.41; p<0.05; d5: 1.09± 0.02; d14: 0.95± 0.2; 
KCC2; ctrl: 1 ± 0.28; d1: 0.46 ± 0.02; p<0.05; d5: 0.73 ± 0.10; d14: 1.16± 0.35).  
Using western blotting we found that the NKCC1 protein levels were significantly increased by 45% 
and 70% of control levels at d1pSE and d5pSE respectively with no significant alteration at d14pSE 
(Figure 1B; ctrl: 1 ± 0.08; d1: 1.45± 0.13; p<0.01; d5: 1.70± 0.24; p<0.05; d14: 1.62± 0.36, when 
normalized to 3-tubulin and ctrl: 1 ± 0.13; d1: 1.29± 0.12; p<0.01; d5: 2.07± 0.22; p<0.05; d14: 
1.23± 0.41, when normalized to 〈-tubulin) when normalized to either 〈-tubulin or 3-tubulin. In 
contrast, the neuron-specific KCC2 protein was significantly reduced to 60% of the control levels at 
d5pSE with a tendency to a partial recovery at d14pSE (Figure 1C; ctrl: 1 ± 0.09; d1: 1.10± 0.17; d5: 
0.58± 0,08; p<0.01; d14: 0.77± 0.16). 
Immunohistochemistry towards KCC2 in pilocarpine-treated rats sections showed a preferential 
cytoplasmic immunoreactivity pattern at d1pSE with a tendency to return to control conditions at 
d14pSE but with lower fluorescence intensity (Figure 1D,E). This is in contrast to control conditions 
where KCC2 immunolabeling showed a strong perisomatic pattern. At d5pSE, KCC2 staining was very 
low and diffuse within the neuron cell bodies. These findings, showing an overall change in KCC2 
neuronal distribution, were consistent within the DG, CA3, and CA1 regions (Figure 1D,E).  
Taken together, our qRT-PCR, immunoblot and immunofluorescence results demonstrate that the 
most drastic dysregulation of both NKCC1 and KCC2 expressions occurred at d5pSE. 
Bumetanide functionally reduces early established ectopic MF sprouting 
A major reorganization of hippocampal network observed in both human patients and animal models 
of TLE is the ectopic MF sprouting
7,30-32
, a phenomenon partly responsible for the generation of 
epileptiform activities in human patients and animal models
11,31 
of
 
TLE. However, although 
extensively studied during the chronic phase
19,33
, it has been poorly assessed during the early stages 
after SE
29,30
. Thus, we asked whether ectopic MF sprouting occurs in parallel to the robust changes in 
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KCC2 and NKCC1 expression observed at d5pSE (Figure 1). Immunohistochemical visualization of rMF 
using synaptoporin (SPO) staining
13,34
 revealed a marked ectopic band in the molecular layer of DG 
and strong staining in the granular cell layer in pilocarpine-treated rats at d5pSE, while we found no 
ectopic band stained in control rats (Figure 2A; arrowheads ctrl: 1 ± 0.05; d5pSE: 5.05 ± 0.04, 
p<0.001). Thus, these results demonstrate that the ectopic MF sprouting is established at d5pSE, 
correlating with the pathological KCC2 and NKCC1 expression pattern.  
We next asked whether abnormal chloride homeostasis might be involved in the early establishment 
of the ectopic MF sprouting. In order to achieve this, we use bumetanide to functionally block 
NKCC1. Because its blood-brain-barrier penetration has been challenged
35,36
, we infused bumetanide 
at a dose of 20μM, in accordance with previous pharmacokinetic studies
37,38
 intracerebrally and 
continuously from d2 to d5pSE, using osmotic minipumps (Figure 2B).  
Interestingly, at d5pSE, we observed a 45% decrease in SPO fluorescence intensity in bumetanide-
treated rats as compared to the vehicle-treated rats (Figure 2C; vehicle-treated rats: 5.03 ± 0.04 vs 
bumetanide-treated: 2.83 ± 0.049; p<0.001, normalized to control). In order to find out whether this 
rMF sprouting is functional as early as d5pSE, we performed the antidromic stimulation of the mossy 
fibers pathway in the CA3b area while recording local field potentials in the DG cell layer
 
(Figure 2D). 
Importantly, we found that the evoked population burst was strongly reduced in bumetanide-treated 
rats as compared to vehicle-treated pilocarpine rats (Figure 2D; vehicle-treated vs bumetanide-
treated: 14326.31± 3853 vs 5252.66 ± 1608; p<0.05).  
Together these results demonstrate that a functional recurrent MF network is already in place at 
d5pSE. Strikingly, the use of bumetanide in vivo functionally reduced this ectopic MF sprouting. 
Bumetanide blocked NKCC1 upregulation and rescued KCC2 function at d5pSE. 
Several in vitro and in vivo studies have shown that bumetanide can affect the functional expression 
of NKCC1
21,22
. To better understand the mechanism by which bumetanide reduced the ectopic MF 
sprouting and its aberrant network activity, we examined the effect of bumetanide on NKCC1 and 
KCC2 expression and function. Here, we show that intracerebral infusion of bumetanide partially 
blocked NKCC1 upregulation. Surprisingly, total KCC2 expression levels were fully restored in 
bumetanide-treated pilocarpine rats as compared to vehicle-treated rats (Figure 3B; NKCC1: vehicle-
treated rats: 2.28 ± 0.10 vs 1.68 ± 0.14; p<0.05, normalized to control. KCC2: vehicle-treated vs 
bumetanide-treated rats: 0.47 ± 0.15 vs 1.40 ± 0.23; p<0.05, normalized to control). Using 
histological analysis, we show that KCC2 displays a preferentially perisomatic staining in bumetanide-
treated rat similar to vehicle-treated rats at d5pSE in the DG, CA3 and CA1 regions (Figure 3D).  
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We next investigated whether bumetanide also restored KCC2 function. To investigate KCC2 ability to 
extrude Cl
-
 we used the whole-cell patch-clamp approach coupled to GABA uncaging in hippocampal 
slices in the CA1 region (Figure 3E). The approach consists of inducing a somatic load of chloride 
through the patch pipette followed by uncaging of GABA at the soma and at a distance of 100μm in 
the apical dendrite. In vehicle-treated rats, we observed that the EGABA gradient was significantly 
smaller (Figure 3E, -0.12 ± 0.005mV/100μm) than in bumetanide-treated rats at d5pSE (Figure 3E, -
0.17 ± 0.007mV/100μm). The later was almost identical to the levels previously measured for this 
age
28
.  
Although there is ample evidence for the specificity of bumetanide as inhibitor of NKCC1 uptake 
activity, when used at low concentration, the effect observed could be derived from nonspecific 
action of this compound due to tissue accumulation. Interestingly, high concentration of bumetanide 
(100µM) exacerbated the KCC2 downregulation observed at d5pSE (Figure 4; DG: vehicle-treated 
rats: 0,44 ± 0,09 vs bumetanide 20-treated: 0,71 ± 0,1; p<0.01 vs bumetanide 100-treated: 0,44 ± 
0,08; p<0.001; CA3: vehicle-treated rats: 0,31 ± 0,12 vs bumetanide 20-treated: 0,53 ± 0,12; p<0.001 
vs bumetanide 100-treated: 0,01 ± 0,11; p<0.001 and CA1: vehicle-treated rats: 0,60 ± 0,10 vs 
bumetanide 20-treated: 0,81 ± 0,13; p<0.01 vs bumetanide 100-treated: 0,35 ± 0,11; p<0.001). This 
result shows that nonspecific effects due to either accumulation of bumetanide and derived 
inhibition of KCC2, would result in opposite effects. Our findings show that intracerebral bumetanide 
infusion from d2 to d5pSE rats at low concentration is specific, able to partially block NKCC1 
expression, and restored not only KCC2 protein expression but also its function at d5pSE within the 
hippocampus.  
p75
NTR 
upregulation drives the ectopic MF sprouting and is blocked by bumetanide 
We have previously shown that, in axotomized organotypic hippocampal slices, altered NKCC1/KCC2 
balance induced p75
NTR 
upregulation that could be prevented by bumetanide
26
. P75
NTR 
is also known 
to play a key role in neurite outgrowth
39,40
 and is crucial for axon formation in the DG under 
physiological conditions
40
. Therefore, we asked whether bumetanide could regulate p75
NTR
 
expression to mediate the effects observed on the ectopic MF sprouting at d5pSE (Figure 5A). Using 
western blot from in toto hippocampi, we found that p75
NTR 
expression level was reduced in 
bumetanide-treated rats as compared to vehicle-treated rats at d5pSE (Figure 5B, vehicle-treated vs 
bumetanide-treated rats: 1.42 ± 0.13 vs 0.90 ± 0.13; p<0.05, normalized to control 1 ± 0.09). Then, 
using immunohistochemistry, we showed that as previously described
41,42
, p75
NTR 
was expressed at 
low level in DGCs in control conditions. Interestingly, bumetanide application strongly reduced the 
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SE-induced abnormal p75
NTR 
expression within the granule cells at d5pSE (Figure 5C, vehicle-treated 
vs bumetanide-treated rats: 1.64 ± 0.04 vs 1.14 ± 0.02; p<0.001, normalized to control).  
Finally, in order to establish if p75
NTR 
upregulation is involved in the formation of ectopic MF 
sprouting, we decided to infuse intracerebrally a previously validated
24
 p75
NTR 
functionally blocking 
antibody (p75
NTR
-Ab) from d2 to d5pSE (Figure 5D for the experimental design). Interestingly, SPO 
staining revealed significantly decreased fluorescence intensity in p75
NTR 
Ab-treated as compared to 
vehicle- or IgG-treated rats at d5pSE (Figure 5D, IgG-treated rats: 6,27 ± 0,57; vehicle-treated vs 
p75
NTR 
Ab-treated rats: 5.06 ± 0.5 vs 3.17 ± 0.24; p<0.001, normalized to control). 
Altogether these results suggest that bumetanide-mediated functional reduction of ectopic MF 
sprouting is, at least partly, mediated by p75
NTR 
upregulation blockade in vivo at d5pSE in the 
pilocarpine model of TLE. 
Early bumetanide infusion reduced seizure frequency during the chronic phase of TLE 
The transient application of bumetanide had profound positive effects on morphological and 
functional reorganization as well as on functional expression of chloride homeostasis regulatory 
proteins within the hippocampal formation during the early post-SE window.  
To examine whether transitory application of bumetanide early after SE had a long-lasting effects, 
we used a similar approach to the one use above with the difference that sprouting is analyzed 
during the chronic and not the early phase of TLE (Figure 6A). The examination of the cortical EEG 
(24h/d) from d2 to d5 post-SE did not reveal interictal and ictal activities under the present 
experimental conditions in vehicle nor bumetanide infused animals (data not shown). However, 
following bumetanide infusion from d2 to d5 post-SE, SPO staining revealed a reduction of the 
ectopic band in the molecular layer of DG in bumetanide-treated rats as compared to vehicle-treated 
rats at 2 months post-SE (Figure 6B; vehicle-treated vs bumetanide treated: 7.34 ± 0,35 vs 6.11 ± 
0,41; p<0.05, normalized to control). This interesting long-lasting effect of bumetanide on ectopic MF 
sprouting prompted us to analyze the seizure activity with telemetric scalp EEG recordings at 2 
months post-SE after the rats underwent the same experimental paradigm as in the previous 
experiments (Figure 6A). In this chronic condition, we observed that the number of ictal events was 
reduced by 50% in the bumetanide-treated group as compared to the vehicle-treated group (Figure 
6C-E: vehicle-treated vs bumetanide treated: 13.94 ± 0,74 vs 7.05 ± 0,39; p<0.05, normalized to 
control), without a significant change in their duration (Figure 6D; vehicle-treated vs bumetanide 
treated: 18.59 ± 0,71 vs 17.65 ± 1.04; p>0.05).  
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Discussion 
Studies on TLE show that a major glutamatergic circuit reorganization within the DG, the 
ectopic rMF, is responsible for an increase in hippocampal excitability and recurrent seizures
1,43
. 
Equally strong evidence has been found showing that adult seizures are generated in a circuit in 
which GABAAR-mediated inhibition is impaired
21,44
. Within this context, compromised GABAergic
inhibition resulting from chloride homeostasis dysregulation in epileptic-like conditions has been 
extensively studied both in animal models and human resections in TLE
19-23
. In these studies, acute 
use of bumetanide, leading to restoration of chloride homeostasis, has been shown to have potent 
anticonvulsant effects in the adult brain. However, whether GABAergic depolarization plays a role in 
the precipitating events of epileptogenesis and could exert long-term effect on morphological and 
functional features of glutamatergic network rewiring and subsequently affect seizure activity has 
not been assessed. Here, we have addressed these issues by using a pilocarpine model of TLE. First, 
we found that early ectopic rMF sprouting and subsequent rMF-driven network aberrant activity was 
established as early as 5 days after the SE. This time point coincided with NKCC1 upregulation and 
KCC2 downregulation. Importantly, we showed that functional inhibition of NKCC1 with the loop 
durietic bumetanide from d2 to d5 post-SE resulted in restoration of chloride homeostasis and 
robust attenuation of rMF-driven network activity during early epileptogenesis. These effects 
extended to the chronic epileptic phase and resulted in strongly reduced seizure frequency. The 
mechanism appears to involve upregulation of the pan neurotrophin receptor p75
NTR 
as inhibition of 
NKCC1 activity significantly reduced the SE-induced upregulation of this receptor. Previous studies 
have suggested the involvement of NGF/TrkA/p75
NTR
 signaling on MF sprouting in a kindling animal 
model
17
. We now also demonstrate that p75
NTR 
is a key factor in the early establishment of the 
ectopic rMF sprouting in TLE as: i) in accordance to previous studies
45,46
 p75
NTR 
is upregulated at 
d5pSE, ii) while bumetanide strongly reduced the ectopic rMF sprouting it also blocked p75
NTR 
upregulation, iii) a functionally blocking p75
NTR 
antibody reduced the ectopic rMF sprouting. 
Furthermore, previous reports suggest a role of GABAAR-mediated depolarization on axonal 
elongation during development and adult neurogenesis
47
. Our results show that early post-SE 
bumetanide application reduces ectopic rMF, p75
NTR
 expression, and chronic seizures. These effects 
are associated with impairment of GABAAR-mediated depolarization by bumetanide through its 
specific inhibitory action on the chloride co-transporter NKCC1. Future investigations are required to 
elucidate the causal relationship between altered GABAergic transmission and aberrant 
neurotrophin signaling under pathological conditions. 
The reported results also suggest that the ectopic MF sprouting, promoted by chloride homeostasis 
dysregulation and p75
NTR
 signaling pathway during early epileptogenesis, plays a key role for the 
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development of chronic seizures since post-SE application of bumetanide reduced the number of 
spontaneous and recurrent seizures in chronic epileptic rats.  
It is plausible that the effects exerted by bumetanide are mediated through an effect on post-SE 
remnant seizure activity. Indeed, bumetanide has been shown to have anticonvulsant action in 
numerous seizure models
25
. Within the early period following SE (2-3 days post-SE), sporadic 
remnant interictal and ictal activities can occur
48,49
. However, in the present experimental paradigm, 
the pilocarpine-treated rats exhibit a seizure-free period from day 2 to day 5 post-SE (data not 
shown). Nonetheless, we cannot exclude an effect of bumetanide on sporadic hippocampal inter-
ictal events that could not be reliably detected from cortical EEG recordings in contrast to seizure 
activity. Further studies are necessary to dissect if and how GABA depolarization is involved in post 
SE network activity during early epileptogenesis.  
 Altogether, the present study suggests that SE-induced depolarizing GABAergic signaling could play a 
mechanistic role in the early and long lasting rewiring of glutamatergic networks that is implicated in 
the severity of chronic seizures. These results also prompt to investigate optimal conditions for 
better and more efficient restriction of seizures in the chronic phase using this approach. 
In the clinical setting of symptomatic and unprovoked epilepsy the use of anti-epileptic drug 
prophylaxis during the acute period following SE is recommended
50,51
. In addition, symptomatic 
epilepsy specially involving the temporal lobe often displays pharmaco-resistance to available 
antiepileptic drugs. Thus, the results presented here prompt us to conclude that normalizing chloride 
homeostasis with the FDA-approved drug bumetanide during the acute posttraumatic period could 
be able to sustainably reduce the pathological glutamatergic network rewiring and subsequent 
chronic adult epilepsy. Moreover, prophylactic approaches to correct dysregulation of GABAergic 
transmission and p75
NTR
 signalling are novel clinically relevant targets that could complement the 
current therapy following acute symptomatic seizures.   
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Figure legends 
Figure 1. Altered NKCC1 and KCC2 expression in hippocampus after Status Epilepticus. (A) Relative 
expression of NKCC1 and KCC2 mRNA transcripts by qRT-PCR of in toto hippocampi as function of 
GAPDH expression. Values are normalized to control rats (n=3 per group). (B) Representative 
immunoblot for NKCC1 protein extracts from in toto hippocampi. Corresponding quantification are 
normalized to ctrl and expressed relative to a-tubulin (dashed bars) and b3-tubulin (empty bars) as 
shown by the bar graph (n=6-7 per group). (C). Representative immunoblot for KCC2 protein extracts 
from in toto hippocampi. Corresponding quantification normalized to ctrl and expressed relative to 
b3-tubulin levels (n=6-7 per group). (D) Representative images of KCC2 (red) and NeuN (green) 
staining in DG (top), CA3 (middle) and CA1 (bottom) regions in control and at d1, d5 and d14 post-SE. 
Insets show a higher magnification of cells pointed by the arrowheads. While in control condition 
KCC2 staining is preferentially perisomatic, following SE the staining is diffuse within the NeuN-
poistive cell bodies. Note that the KCC2 staining is very low at d5pSE. DG: dentate gyrus; CA: Cornu 
Ammonis; a.u.: arbitrary unit.(E) Average curve profile of KCC2 staining in DG, CA3, and CA1 regions 
at day 1, 5, and 14 post-SE (n=3-4 per group). The curves represent the plot profile of KCC2 staining 
along 10µm from the nucleus to the external neuropil of the neurons analyzed. Notice that in control 
condition but not following SE, peak of KCC2 immunofluorescence occurs at the putative membrane 
location (arrowhead). Data are means ± SEM; p value obtained using t test analysis; * p<0.05; ** 
p<0.01, *** p<0.001. Scale bars are 10µm for insets and 100µm for full pictures. 
Figure 2. In vivo bumetanide functionally reduces ectopic MFs sprouting at d5pSE. (A) Left, 
Immunolabelling of synaptoporin (SPO) of mossy fibers. Ectopic rMF sprouting is observed in the 
molecular layer of both ventral and dorsal DG in pilocarpine-treated rats and is absent in control rats 
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(arrowheads). Insets show higher magnification of the region depicted by the white squares. DG: 
dentate gyrus. Right, corresponding quantification of the fluorescence intensity normalized to 
control condition. Data are mean ± SEM (n=3 control rats and n=6 pilocarpine-treated for d5pSE); 
*** p<0.001, p value are obtained using t test analysis. Scale bar represents 150µm. (B) Experimental 
paradigm design. Bumetanide or vehicle solutions are infused intracerebrally from d2 to d5pSE using 
osmotic minipumps and experiments are performed at d5pSE. SE: status epilepticus. (C) SPO staining 
revealed an ectopic rMF band in the molecular layer of the DG in vehicle-treated rats that was 
strongly reduced in bumetanide-treated rats and absent under control condition (arrowheads). 
Insets show higher magnification of the region depicted by the white squares. DG: dentate gyrus. 
Corresponding quantification of the fluorescence intensity of synaptoporin in vehicle- and 
bumetanide-treated d5pSE rats normalized to control condition. (n=3 for control rats; n=5-6 vehicle- 
and bumetanide-treated rats). Scale bar represents 150µm; *** p<0.001, using Tukey multiple-
comparison test two-way ANOVA analysis. (D) Top, scheme of hippocampal slice with the CA3c-DG 
antidromic stimulation protocol. Traces are average of 100 sweeps in both conditions. The arrow 
shows an antidromic population spike followed by a burst (arrowhead). Estim: stimulation electrode in 
CA3c region; Erec: recording electrode in DG cell layer. Down, corresponding bar graph represents the 
mean coastline burst index observed in slices from vehicle and bumetanide-treated d5pSE rats. (n=3-
4 rats for vehicle- or bumetanide-treated rats).  
Figure 3. In vivo bumetanide application rescues NKCC1 expression and KCC2 function at d5pSE. (A) 
Experimental paradigm design. Bumetanide or vehicle solutions are infused intracerebrally from d2 
to d5pSE using osmotic minipumps and experiments are performed at d5pSE. (B) Representative 
immunoblot for NKCC1 protein extracts from in toto hippocampus under control condition, after 
vehicle or bumetanide infusion at d5pSE. Corresponding quantification normalized to ctrl and 
expressed relative to a-tubulin levels (n=4-6 per group) (C) Representative immunoblot for KCC2 
protein extracts from in toto hippocampus under control condition, after vehicle or bumetanide 
infusion at d5pSE. Corresponding quantification are shown in the bar graph. The data are normalized 
to ctrl and expressed relative to b3-tubulin levels. (n=4-6 per group). (D) Left, KCC2 staining (red) in 
DG (top), CA3 (middle) and CA1 (bottom) regions in control, vehicle-treated d5pSE, and bumetanide-
treated d5pSE rats (n=3 for control, n=5-6 for vehicle- or bumetanide-treated). Scale bar represents 
100µm. Right, Average curve profile of KCC2 staining in DG, CA3, and CA1 regions at different days 
post-SE in vehicle- and bumetanide-treated rats. The curves represent the plot profile of KCC2 
staining along 10µm from the nucleus to the external neuropil of the neurons analysed in control 
(black), vehicle-treated (blue) and bumetanide-treated (red) conditions. Notice that KCC2 intensity 
and pattern expression recovered to control conditions following bumetanide application as shown 
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by the images and plot profile. (E) Left, the scheme represents the whole-cell patch-clamp recordings 
of uncaging GABAA-mediated currents (IGABA) and DEGABA between soma and dendrite of a pyramidal 
neuron from CA1 region with an artificially imposed somatic Cl
- 
load. IGABA: GABAA-mediated currents;
EGABA: GABA reversal potential; UV: 405nm light stimuli for GABA uncaging (50ms); Vm: resting 
membrane potential. Representative currents of the soma and dendrites are shown following UV-
induced GABA uncaging. Middle, the I/V curve obtained in neurons from vehicle- (blue curves) or 
bumetanide-treated (red curves) animals at d5pSE. The arrow shows that the soma-to-dendrite 
gradient is greater following in vivo bumetanide application. Insets show the current following UV 
light (line) in dendrties (upper panel) and soma (lower panel). Right, bar graph represents the 
quantification of the imposed soma-to-dendrite DEGABA under vehicle- and bumetanide-treated 
condition at d5pSE. (n=3-4 per group). Data are means ± SEM; *p<0.05, *** p<0.001, p value 
obtained using two-way ANOVA in (B, C, D) and Mann-Whitney U test in (E). 
Figure 4. In vivo infusion of high dose bumetanide alters KCC2 expression at d5pSE. (A) KCC2 
staining in DG (top), CA3 (middle) and CA1 (bottom) regions in pilocarpine vehicle-treated, 20µM 
bumetanide-treated and 100µM bumetanide-treated rats. Note that following high dose of 
bumetanide application, KCC2 intensity is very low as compared to low dose of bumetanide. DG: 
dentate gyrus; CA: Cornu Ammonis; a.u.: arbitrary unit. Scale bar is 10µm. (B) Corresponding bar 
graph of global KCC2 fluorescence intensity, in the DG, CA3 and CA1 regions. (n=3-4 per group). Data 
are means ± SEM; ** p<0.01, and *** p<0.001, using Tukey multiple-comparison test two-way 
ANOVA analysis.  
Figure 5. Bumetanide-induced ectopic MF sprouting reduction involves post-SE induced p75
NTR
 up-
regulation. (A) Scheme summarizing working hypothesis. Bumetanide restored NKCC1/KCC2 balance 
and reduced ectopic MF sprouting. We next ask whether p75
NTR 
could mediate this effect. (B)
Representative immunoblot for p75
NTR
 protein extracts from in toto hippocampus in vehicle- and 
bumetanide-treated rats at d5pSE. Right, corresponding quantification normalized to ctrl and 
expressed relative to GADPH levels (n=3-4 per group). (C) Top, experimental paradigm design. 
Bumetanide or vehicle solutions are infused intracerebrally from d2 to d5pSE and 
immunohistochemical analysis of p75
NTR
 is performed at d5pSE. Bottom, p75
NTR
 immunostaining 
performed in DG of control, vehicle- and bumetanide-treated rats. Granular cells are p75
NTR
 positive 
(arrowhead) and immunoreactivity surrounding the granular cell layer in control condition and under 
vehicle or bumetanide condition. Corresponding fluorescence intensity quantification is shown by 
the bar graph; values are normalized to ctrl (n=3 for ctrl, n=4-6 for vehicle-or bumetanide-treated 
rats). (D) Top, illustration of experimental procedure. Intracerebral infusion of blocking p75
NTR
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antibody performed from d2 to d5pSE and analysis of the ectopic MF sprouting at d5pSE. Bottom, 
synaptoporin revealed an ectopic MF band in the molecular layer of the DG in vehicle- and IgG-
treated rats that was faint in p75
NTR
 antibody-treated rats (arrowhead). Corresponding quantification 
of the fluorescence intensity normalized to control condition (n=3 for ctrl, n=4-6 for vehicle-or 
bumetanide-treated rats). Data are means ± SEM; *p<0.05, *** p<0.001, p value are obtained using 
using Tukey multiple-comparison test two-way ANOVA analysis. Scale bar represents 150µm. 
Figure 6. Early bumetanide application reduces rMFS and seizures in vivo at 2 months post-SE. (A) 
Experimental paradigm design and example of seizure recorded at 2 months post-SE using telemetric 
EEG. Bumetanide or vehicle solutions are infused intracerebrally from d2 to d5pSE. The seizure 
frequency and rMF sprouting is assessed 2 months after the end of bumetanide infusion using scalp 
electrodes and telemetric EEG as well as histological studies. (B) Synaptoporin staining labeled the 
mossy fibers and revealed a strong ectopic MF band in the molecular layer of the DG (arrowheads) of 
vehicle-treated rats. The intensity of this band was clearly decreased in bumetanide-treated animals. 
The corresponding bar graph represents the quantification of the fluorescence intensity of the 
ectopic MF sprouting in vehicle- and bumetanide-treated d5pSE rats normalized to control condition. 
Data are means ± SEM; *p<0.05, *** p<0.01 p value are obtained using Tukey multiple-comparison 
test two-way ANOVA analysis. (C) Examples of typical ictal events recorded using telemetric EEG in 
vehicle-treated and bumetanide-treated rats at 2MpSE. Arrows show the start of seizure and 
arrowheads the end of seizure. (D) Left, distribution of electrographic seizures over 24h (day/night 
period) for vehicle-treated (blue) and bumetanide-treated rats (red). Right, pie chart showing the 
fraction of ictal events recorded in vehicle- and bumetanide-treated rats over 5 days, 24/24h 
recording (219 and 114 ictal events, respectively; n=4 rats per group). (E) Left, bar graph representing 
the seizure frequency observed in vehicle- and bumetanide-treated rats per day. Data are means ± 
SEM; *p<0.05, p value are obtained using Mann-Whitney U test. Right, bar graph showing the 
duration of ictal events in vehicle-treated and bumetanide-treated rats. (n=4 per group). Data are 
means ± SEM; p>0.05 using Mann-Whitney U test.  
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Figure 1. Altered NKCC1 and KCC2 expression in hippocampus after Status Epilepticus. (A) Relative 
expression of NKCC1 and KCC2 mRNA transcripts by qRT-PCR of in toto hippocampi as function of GAPDH 
expression. Values are normalized to control rats (n=3 per group). (B) Representative immunoblot for 
NKCC1 protein extracts from in toto hippocampi. Corresponding quantification are normalized to ctrl and 
expressed relative to α-tubulin (dashed bars) and β3-tubulin (empty bars) as shown by the bar graph (n=6-
7 per group). (C). Representative immunoblot for KCC2 protein extracts from in toto hippocampi. 
Corresponding quantification normalized to ctrl and expressed relative to β3-tubulin levels (n=6-7 per 
group). (D) Representative images of KCC2 (red) and NeuN (green) staining in DG (top), CA3 (middle) and 
CA1 (bottom) regions in control and at d1, d5 and d14 post-SE. Insets show a higher magnification of cells 
pointed by the arrowheads. While in control condition KCC2 staining is preferentially perisomatic, following 
SE the staining is diffuse within the NeuN-poistive cell bodies. Note that the KCC2 staining is very low at 
d5pSE. DG: dentate gyrus; CA: Cornu Ammonis; a.u.: arbitrary unit.(E) Average curve profile of KCC2 
staining in DG, CA3, and CA1 regions at day 1, 5, and 14 post-SE (n=3-4 per group). The curves represent 
the plot profile of KCC2 staining along 10µm from the nucleus to the external neuropil of the neurons 
analyzed. Notice that in control condition but not following SE, peak of KCC2 immunofluorescence occurs at 
the putative membrane location (arrowhead). Data are means ± SEM; p value obtained using t test 
analysis; * p<0.05; ** p<0.01, *** p<0.001. Scale bars are 10µm for insets and 100µm for full pictures. 
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Figure 2. In vivo bumetanide functionally reduces ectopic MFs sprouting at d5pSE. (A) Left, Immunolabelling 
of synaptoporin (SPO) of mossy fibers. Ectopic rMF sprouting is observed in the molecular layer of both 
ventral and dorsal DG in pilocarpine-treated rats and is absent in control rats (arrowheads). Insets show 
higher magnification of the region depicted by the white squares. DG: dentate gyrus. Right, corresponding 
quantification of the fluorescence intensity normalized to control condition. Data are mean ± SEM (n=3 
control rats and n=6 pilocarpine-treated for d5pSE); *** p<0.001, p value are obtained using t test 
analysis. Scale bar represents 150µm. (B) Experimental paradigm design. Bumetanide or vehicle solutions 
are infused intracerebrally from d2 to d5pSE using osmotic minipumps and experiments are performed at 
d5pSE. SE: status epilepticus. (C) SPO staining revealed an ectopic rMF band in the molecular layer of the 
DG in vehicle-treated rats that was strongly reduced in bumetanide-treated rats and absent under control 
condition (arrowheads). Insets show higher magnification of the region depicted by the white squares. DG: 
dentate gyrus. Corresponding quantification of the fluorescence intensity of synaptoporin in vehicle- and 
bumetanide-treated d5pSE rats normalized to control condition. (n=3 for control rats; n=5-6 vehicle- and 
bumetanide-treated rats). Scale bar represents 150µm; *** p<0.001, using Tukey multiple-comparison test 
two-way ANOVA analysis. (D) Top, scheme of hippocampal slice with the CA3c-DG antidromic stimulation 
protocol. Traces are average of 100 sweeps in both conditions. The arrow shows an antidromic population 
spike followed by a burst (arrowhead). Estim: stimulation electrode in CA3c region; Erec: recording electrode 
in DG cell layer. Down, corresponding bar graph represents the mean coastline burst index observed in 
slices from vehicle and bumetanide-treated d5pSE rats. (n=3-4 rats for vehicle- or bumetanide-treated 
rats). 
1057x881mm (72 x 72 DPI) 
Page 23 of 28
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
Figure 3. In vivo bumetanide application rescues NKCC1 expression and KCC2 function at d5pSE. (A) 
Experimental paradigm design. Bumetanide or vehicle solutions are infused intracerebrally from d2 to d5pSE 
using osmotic minipumps and experiments are performed at d5pSE. (B) Representative immunoblot for 
NKCC1 protein extracts from in toto hippocampus under control condition, after vehicle or bumetanide 
infusion at d5pSE. Corresponding quantification normalized to ctrl and expressed relative to α-tubulin levels 
(n=4-6 per group) (C) Representative immunoblot for KCC2 protein extracts from in toto hippocampus 
under control condition, after vehicle or bumetanide infusion at d5pSE. Corresponding quantification are 
shown in the bar graph. The data are normalized to ctrl and expressed relative to β3-tubulin levels. (n=4-6 
per group). (D) Left, KCC2 staining (red) in DG (top), CA3 (middle) and CA1 (bottom) regions in control, 
vehicle-treated d5pSE, and bumetanide-treated d5pSE rats (n=3 for control, n=5-6 for vehicle- or 
bumetanide-treated). Scale bar represents 100µm. Right, Average curve profile of KCC2 staining in DG, 
CA3, and CA1 regions at different days post-SE in vehicle- and bumetanide-treated rats. The curves 
represent the plot profile of KCC2 staining along 10µm from the nucleus to the external neuropil of the 
neurons analysed in control (black), vehicle-treated (blue) and bumetanide-treated (red) conditions. Notice 
that KCC2 intensity and pattern expression recovered to control conditions following bumetanide application 
as shown by the images and plot profile. (E) Left, the scheme represents the whole-cell patch-clamp 
recordings of uncaging GABAA-mediated currents (IGABA) and ∆EGABA between soma and dendrite of a 
pyramidal neuron from CA1 region with an artificially imposed somatic Cl- load. IGABA: GABAA-mediated 
currents; EGABA: GABA reversal potential; UV: 405nm light stimuli for GABA uncaging (50ms); Vm: resting 
membrane potential. Representative currents of the soma and dendrites are shown following UV-induced 
GABA uncaging. Middle, the I/V curve obtained in neurons from vehicle- (blue curves) or bumetanide-
treated (red curves) animals at d5pSE. The arrow shows that the soma-to-dendrite gradient is greater 
following in vivo bumetanide application. Insets show the current following UV light (line) in dendrties 
(upper panel) and soma (lower panel). Right, bar graph represents the quantification of the imposed soma-
to-dendrite ∆EGABA under vehicle- and bumetanide-treated condition at d5pSE. (n=3-4 per group). Data are 
means ± SEM; *p<0.05, *** p<0.001, p value obtained using two-way ANOVA in (B, C, D) and Mann-
Whitney U test in (E). 
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Figure 4. In vivo infusion of high dose bumetanide alters KCC2 expression at d5pSE. (A) KCC2 staining in 
DG (top), CA3 (middle) and CA1 (bottom) regions in pilocarpine vehicle-treated, 20µM bumetanide-treated 
and 100µM bumetanide-treated rats. Note that following high dose of bumetanide application, KCC2 
intensity is very low as compared to low dose of bumetanide. DG: dentate gyrus; CA: Cornu Ammonis; a.u.: 
arbitrary unit. Scale bar is 10µm. (B) Corresponding bar graph of global KCC2 fluorescence intensity, in the 
DG, CA3 and CA1 regions. (n=3-4 per group). Data are means ± SEM; ** p<0.01, and *** p<0.001, using 
Tukey multiple-comparison test two-way ANOVA analysis. 
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Figure 5. Bumetanide-induced reduction of  ectopic MF sprouting involves post-SE induced p75NTR up-
regulation. (A) Scheme summarizing working hypothesis. Bumetanide restored NKCC1/KCC2 balance and 
reduced ectopic MF sprouting. We next ask whether p75NTR could mediate this effect. (B) Representative 
immunoblot for p75NTR protein extracts from in toto hippocampus in vehicle- and bumetanide-treated rats at 
d5pSE. Right, corresponding quantification normalized to ctrl and expressed relative to GADPH levels (n=3-4 
per group). (C) Top, experimental paradigm design. Bumetanide or vehicle solutions are infused 
intracerebrally from d2 to d5pSE and immunohistochemical analysis of p75NTR is performed at d5pSE. 
Bottom, p75NTR immunostaining performed in DG of control, vehicle- and bumetanide-treated rats. Granular 
cells are p75NTR positive (arrowhead) and immunoreactivity surrounding the granular cell layer in control 
condition and under vehicle or bumetanide condition. Corresponding fluorescence intensity quantification is 
shown by the bar graph; values are normalized to ctrl (n=3 for ctrl, n=4-6 for vehicle-or bumetanide-
treated rats). (D) Top, illustration of experimental procedure. Intracerebral infusion of blocking p75NTR 
antibody performed from d2 to d5pSE and analysis of the ectopic MF sprouting at d5pSE. Bottom, 
synaptoporin revealed an ectopic MF band in the molecular layer of the DG in vehicle- and IgG-treated rats 
that was faint in p75NTR antibody-treated rats (arrowhead). Corresponding quantification of the fluorescence 
intensity normalized to control condition (n=3 for ctrl, n=4-6 for vehicle- or bumetanide-treated rats). Data 
are means ± SEM; *p<0.05, *** p<0.001, p value are obtained using using Tukey multiple-comparison test 
two-way ANOVA analysis. Scale bar represents 150µm. 
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Figure 6. Early bumetanide application reduces rMFS and seizures in vivo at 2 months post-SE. (A) 
Experimental paradigm design and example of seizure recorded at 2 months post-SE using telemetric EEG. 
Bumetanide or vehicle solutions are infused intracerebrally from d2 to d5pSE. The seizure frequency and rMF 
sprouting is assessed 2 months after the end of bumetanide infusion using scalp electrodes and telemetric 
EEG as well as histological studies. (B) Synaptoporin staining labeled the mossy fibers and revealed a strong 
ectopic MF band in the molecular layer of the DG (arrowheads) of vehicle-treated rats. The intensity of this 
band was clearly decreased in bumetanide-treated animals. The corresponding bar graph represents the 
quantification of the fluorescence intensity of the ectopic MF sprouting in vehicle- and bumetanide-treated 
d5pSE rats normalized to control condition. Data are means ± SEM; *p<0.05, *** p<0.01 p value are 
obtained using Tukey multiple-comparison test two-way ANOVA analysis. (C) Examples of typical ictal 
events recorded using telemetric EEG in vehicle-treated and bumetanide-treated rats at 2MpSE. Arrows 
show the start of seizure and arrowheads the end of seizure. (D) Left, distribution of electrographic seizures 
over 24h (day/night period) for vehicle-treated (blue) and bumetanide-treated rats (red). Right, pie chart 
showing the fraction of ictal events recorded in vehicle- and bumetanide-treated rats over 5 days, 24/24h 
recording (219 and 114 ictal events, respectively; n=4 rats per group). (E) Left, bar graph representing the 
seizure frequency observed in vehicle- and bumetanide-treated rats per day. Data are means ± SEM; 
*p<0.05, p value are obtained using Mann-Whitney U test. Right, bar graph showing the duration of ictal
events in vehicle-treated and bumetanide-treated rats. (n=4 per group). Data are means ± SEM; p>0.05
using Mann-Whitney U test. 
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Table 1 : list of primers for qRT-PCR and antibodies for western blot and immuhistology 
Name Gene Name Ref. Seq. Cat. N° 
Rn_gapd_1_SG Gapdh glyceraldehyde-3-phosphate dehydrogenase NM_017008.4 QT00199633 
Rn_RGD:620811_1_SG Slc12a5 potassium chloride co-transporter 2 NM_134363 QT00179039 
Rn_Slc12a2_1_SG Slc12a2 sodium potassium chloride co-transporter 1 NM_031798 QT00187173 
Rn_Gfap_1_SG gfap glial fibrillary acidic protein NM_017009 QT00195517 
 Antibodies (Ab) used for Western Blot and Immunoistochemistry 
Ab type Ab name Isotype Source Dilution 
Western Blot 
Primary 
GAPDH mouse Sigma 1/1000 
KCC2 rabbit Chemicon 1/2000 
NKCC1 T4 rabbit DAKO 1/1000 
α-tubulin mouse Covance 1/10 000 
β-tubulin mouse Covance 1/10 000 
p75NTR SC-8317  rabbit  Santa cruz 1/1000 
Secondary 
HRP 1 mouse DAKO 1/3000 
HRP 2 rabbit GE healthcare 1/3000 
IHC 
Primary 
panKCC2 rabbit non commercial 1/4000 
Synaptoporin rabbit Synaptic Systems 1/300 
 P75NTR  rabbit  R&D systems  1/500 
Secondary 
Alexa 488 mouse Molecular Probes 1/500 
Alexa 555 rabbit Molecular Probes 1/500 
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